文献速递类风湿关节炎

抗环瓜氨酸蛋白抗体、骨侵蚀与类风湿因子和疾病活动度及工作生产力的关联:一项患者登记研究

Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
PubMed 文献 · Semin Arthritis Rheum · 2017-10-13

该研究基于布莱根妇女医院类风湿关节炎序贯研究(BRASS)前瞻性登记数据,分析1309例成人类风湿关节炎患者。抗CCP阳性者较阴性者发生骨侵蚀的OR为2.72(95%CI 1.77-4.18,P<0.001);抗CCP阳性合并骨侵蚀者疾病活动度更高、住院、使用耐用医疗设备及失业/残疾的比例更高。

要点

  • 抗CCP阳性者较阴性者骨侵蚀风险升高,OR=2.72(95%CI 1.77-4.18,P<0.001)。
  • 抗CCP阳性合并骨侵蚀者更易出现DAS28-CRP≥2.6、住院、使用耐用医疗设备及失业或残疾。
  • RF阳性者较阴性者骨侵蚀风险无统计学显著差异(95%CI 0.88-2.08,P=0.162)。

核心结论

  • 在真实世界环境中,抗CCP阳性合并骨侵蚀与更差的临床和健康经济学结局显著相关,包括低疾病活动度概率更低和更高的医疗资源利用,尽管许多患者使用了生物制剂改善病情抗风湿药。
  • 作者认为这种双重表现可能提示需要更密集的治疗,即使在慢性及新发类风湿关节炎患者中观察到亦然。

研究设计与样本

  • 研究分析了布莱根妇女医院类风湿关节炎序贯研究(BRASS)的数据,该研究为成人类风湿关节炎患者的前瞻性登记,纳入已确诊或新发患者。
  • 采用逻辑回归模型检验抗CCP/RF血清阳性与骨侵蚀的关联,以及抗CCP/RF血清阳性合并骨侵蚀与类风湿关节炎严重程度、住院、耐用医疗设备使用和工作者生产力之间的关联。
  • 模型协变量包括患者年龄、性别、种族、体重指数、合并症数量和治療。
  • 共纳入1309名登记患者。

主要发现

  • 抗CCP阳性者较阴性者发生骨侵蚀的OR为2.72(95%CI 1.77-4.18,P<0.001)。
  • RF阳性者较阴性者发生骨侵蚀的OR对应的95%CI为0.88-2.08(P=0.162),原文未报告点估计值。
  • 抗CCP血清阳性合并骨侵蚀者显著更可能具有更高的疾病活动度(DAS28-CRP≥2.6)、住院、使用耐用医疗设备以及失业、残疾或长期残疾。

关键数值与推荐

  • 抗CCP阳性(对比阴性)与骨侵蚀的OR=2.72(95%CI 1.77-4.18,P<0.001)。
  • RF阳性(对比阴性)与骨侵蚀的OR对应95%CI为0.88-2.08(P=0.162)。
  • 抗CCP血清阳性合并骨侵蚀与DAS28-CRP≥2.6、住院、使用耐用医疗设备和失业/残疾/长期残疾显著相关。

临床怎么用

  • 原文结论指出,抗CCP阳性合并骨侵蚀可能提示需要更密集的治疗,即使在慢性及新发类风湿关节炎患者中观察到亦然,此為作者观点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate associations between the presence of anti-cyclic citrullinated protein antibodies (anti-CCP) and rheumatoid factor (RF) and other outcomes, including joint erosions and both clinical and economic endpoints, in patients with rheumatoid arthritis (RA). METHODS: Data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS), a prospective registry of adult RA patients with established or recent-onset RA, were analyzed. Logistic regression models were constructed to test associations between anti-CCP/RF seropositivity and erosive disease and the presence of anti-CCP/RF seropositivity plus erosive disease and (1) RA severity; (2) hospitalizations; (3) durable medical equipment (DME) use; and (4) worker productivity (e.g., employment status). Covariates in these models included patient age, gender, race, body mass index (BMI), number of comorbidities, and treatment. RESULTS: Among 1309 registrants, those who were positive (vs. negative) for anti-CCP were 2.72 times more likely to have erosions (OR = 2.72; 95% CI: 1.77-4.18; P < 0.001). Individuals positive (vs. negative) for RF were 36% more likely to have erosions (95% CI: 0.88-2.08; P = 0.162). Patients with anti-CCP seropositivity and erosions were significantly more likely to: (1) have higher disease activity as measured by the Disease Activity Score in 28 joints C-reactive protein (DAS28-CRP ≥ 2.6); (2) be hospitalized; (3) use DME; and (4) be unemployed, disabled, or long-term disabled. CONCLUSIONS: For the first time in a "real-world" setting including patients with both recent-onset and chronic RA, this study demonstrated that the combination of anti-CCP seropositivity and erosions were significantly associated with more adverse clinical and health-economic consequences, including a lower probability of low disease activity and higher health resource utilization, despite use of biologic disease-modifying antirheumatic drugs by many patients. This dual presentation may signal a need for more intensive therapies, even when observed in patients with chronic, as well as recent-onset, RA. Trial registration [Brigham and Women's Hospital (BWH) Rheumatoid Arthritis Sequential Study; Registry URL: https://clinicaltrials.gov/ct2/show/NCT01793103; ClinicalTrials.gov Identifier NCT01793103].

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Alemao E, Guo Z, Frits ML, et al. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study. Semin Arthritis Rheum. 2017. PMID: 29241640. doi:10.1016/j.semarthrit.2017.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。